Advances in immunotherapy for gastric cancer

Gastric cancer is a common malignant tumor worldwide, and its incidence and mortality rate has been among the highest. Most of the tumor stages of gastric cancer in China are intermediate and advanced, with unsatisfactory five-year survival rates and poor prognosis. Although traditional chemotherapy...

Full description

Saved in:
Bibliographic Details
Published inZhongguo lin chuang yan jiu Vol. 36; no. 2; pp. 161 - 165
Main Author CHANG Rui-min, YANG Yang, LIU Bao-rui
Format Journal Article
LanguageChinese
Published The Editorial Department of Chinese Journal of Clinical Research 01.02.2023
Subjects
adoptive immunocyte therapy
gastric cancer
immune checkpoint inhibitors
immunotherapy
tumor-specific vaccine
Online AccessGet full text

Cover

More Information
Summary:Gastric cancer is a common malignant tumor worldwide, and its incidence and mortality rate has been among the highest. Most of the tumor stages of gastric cancer in China are intermediate and advanced, with unsatisfactory five-year survival rates and poor prognosis. Although traditional chemotherapy regimens centered on fluorouracil and platinum have been the primary choice of first-line treatment in the past decades, they have brought limited long-term survival benefits. Immunotherapy, a current research hotspot and emerging therapeutic approach in the field of oncology treatment, has been proven in several clinical studies to significantly improve the survival of patients with intermediate to advanced gastric cancer. This article introduces research advances in immunotherapy including immune checkpoint inhibitors, adoptive cell therapy, and tumor-specific vaccines, aiming to provide new thinking and direction for immunotherapy of gastric cancer.
ISSN:1674-8182
DOI:10.13429/j.cnki.cjcr.2023.02.001